Holista and SCC Launch $1.6 Million JV for Collie Nano-Collagen Plant

JV Agreement Signals Expansion of Collagen Production

Holista Colltech Limited (ASX:HCT) has taken a significant stride towards scaling its collagen technology with a binding joint venture agreement alongside Hong Kong-listed Swang Chai Chuan Limited (HKEX:2321). The partnership will fund, develop, and operate a nano-collagen production facility in Collie, Western Australia, with SCC contributing approximately A$1.6 million to the effort. This JV marks a clear pivot from research to commercial manufacturing, aiming to tap into nutraceutical, food, cosmetic, and biomedical markets.

Holista will hold an initial 50% stake in the JV vehicle, Ovicoll Pty Ltd, with equal board representation ensuring shared governance. Notably, Holista will manage day-to-day operations, leveraging its expertise to oversee the facility's commissioning and production ramp-up. The company also retains ownership of all intellectual property, licensing its technology to the JV in exchange for an 8% royalty on gross sales, capped at 20% of pre-tax profits.

Financial Structure and Shareholder Guarantees

SCC’s A$1.6 million capital injection covers commissioning and initial working capital, with Holista agreeing to pay a 3% annual return on this funding for two years. The JV agreement includes an option for Holista to increase its ownership to 75% between two and five years after SCC’s contribution, based on a pre-agreed valuation. This option provides Holista flexibility to consolidate control if the venture proves successful.

Interestingly, Dr Rajen Manicka, a substantial Holista shareholder, has provided a personal guarantee to SCC covering certain JV financial obligations. This guarantee is secured against his Holista shares but does not impose direct obligations on the company itself. This arrangement introduces an element of personal risk for a key stakeholder, underscoring the importance of the JV's commercial success.

Strategic Importance Amid Legal and Market Challenges

The Collie facility JV aligns with Holista’s broader strategy to commercialise its proprietary collagen technology and establish scalable production capabilities. The move comes as the company navigates ongoing legal disputes and market headwinds, including a recent settlement of a US$1.8 million judgment that had weighed on investor sentiment. This JV could provide a fresh revenue stream and help stabilise Holista’s financial position.

Swang Chai Chuan’s regional market expertise is expected to bolster the JV’s commercialisation efforts, leveraging its distribution networks to accelerate product uptake. The facility’s output targets high-value nano-collagen products, which are in demand across multiple sectors seeking innovative health and wellness solutions.

While commissioning timelines and production targets remain undisclosed, the JV’s formation without material conditions precedent suggests a smooth path forward. Holista has committed to updating the market on development milestones, which will be critical indicators of progress and potential impact on earnings.